Review Article
Elbasvir/Grazoprevir: A Review of the Latest Agent in the Fight against Hepatitis C
Table 1
SVR
12 rates of first-line therapies for the treatment of HCV genotypes 1a, 1b, and 4 [
13,
28–
32].
| | | SVR12 in treatment-naïve patients | | | Overall | Genotype 1a | Genotype 1b | Genotype 4 |
| | Grazoprevir-elbasvir [13] | 95% | 92% | 99% | 100% | | Ledipasvir-sofosbuvir [28] | 100% | NA | NA | NA | | Paritaprevir-ritonavir-ombitasvir + dasabuvir [29] | 91.8% | 92.2% | 100% | NA | | Simeprevir + sofosbuvir [30, 31] | 93% | NA | NA | NA | | Daclatasvir + sofosbuvir [32] | 100% | NA | NA | NA |
|
|
NA: not applicable.
|
